-
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
28 Mar 2024 12:15 GMT
… corporate update at the MedInvest Biotech and Pharma Investor Conference. … more than 30 years of drug development experience, uses its … of these FDA-approved drugs while maintaining the existing … will benefit from each NGC drug. Currently under development are …
-
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
28 Mar 2024 12:00 GMT
… clinical trial design, drug manufacturing and nonclinical studies … is a clinical-stage biotechnology company discovering and developing … best-in-class antiviral drugs. For further information about … of preclinical and clinical drug candidates, our expectations …
-
Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia
28 Mar 2024 11:00 GMT
MONTREAL and CHARLOTTE, N.C., March 28, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the …
-
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
28 Mar 2024 12:05 GMT
… , will present at the MedInvest Biotech & Pharma Investor Conference being … a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA …
-
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
28 Mar 2024 11:00 GMT
… tumor immune evasion and drug resistance, today announced … Molecular Therapeutics
Session Title: Drug Resistance 2: Ras … the conference. About Purple Biotech Purple Biotech Ltd. (NASDAQ… ; the fact that drug development and commercialization involves …
-
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
28 Mar 2024 11:21 GMT
… U.S. Food and Drug Administration (FDA). Following discussions … be administered vehicle (the drug product without the active …
Aldeyra Therapeutics is a biotechnology company devoted to discovering … is an investigational new drug candidate in development for …
-
Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference
28 Mar 2024 12:00 GMT
… INDP), a clinical stage biotechnology company dedicated to pioneering innovative … overview at the MedInvest Biotech & Pharma Investor … participate in the MedInvest Biotech & Pharma Investor … non-steroidal anti-inflammatory drug, or an approved, …
-
Unlocking the potential of natural products in drug discovery
28 Mar 2024 09:45 GMT
… compounds and pinpointing promising drug targets. The additional dimension … A new breed of biotechs like Enveda Biosciences are … posited that natural product drugs, or those closely mimicking … activity, chemical structure and drug-like properties directly from …
-
Korea’s CMO ramp-up lures biotech investors
28 Mar 2024 09:24 GMT
… 2016, global pharmaceutical and biotech firms started building their research … Zone.
“As Songdo’s drug manufacturing capacity has increased … years, the demand for drug materials and lab supplies … of materials and equipment for drug making,” the official said …
-
Malignant Ascites Market to witness growth by 2034, estimates DelveInsight | Lindis Biotech, Wuhan YZY Biopharma, others
28 Mar 2024 06:50 GMT
Malignant Ascites companies are Lindis Biotech, Wuhan YZY Biopharma, AstraZeneca … the market are Lindis Biotech, Wuhan YZY Biopharma, … sales of each drug.
Malignant Ascites Drugs Uptake helps in … upcoming years are Lindis Biotech, Wuhan YZY Biopharma, …